AstraZeneca says AI has yet to yield clinical candidates but could lower risk in late-stage trials

AstraZeneca's chief executive Pascal Soriot told reporters that the company's AI‑driven efforts in drug design have not yet produced a candidate that has entered clinical testing.

He added that the firm believes the technology can be valuable for de‑risking programs that are already in late‑stage development, potentially improving the odds of success.

The comment comes as the industry continues to explore artificial‑intelligence tools to accelerate discovery and streamline regulatory filings, though AstraZeneca has not disclosed any specific projects or timelines.

Soriot’s remarks suggest the company is positioning AI as a support tool rather than a source of new pipelines at this stage.